Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: A case report

Üstün C., Çelebi H., Arat M., ÖZCAN M., Dilek I., GÜRMAN G., ...More

Therapeutic Apheresis, vol.3, no.3, pp.275-277, 1999 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 3 Issue: 3
  • Publication Date: 1999
  • Doi Number: 10.1046/j.1526-0968.1999.00135.x
  • Journal Name: Therapeutic Apheresis
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.275-277
  • Keywords: ABO mismatch, Allogeneic peripheral blood stem cell transplantation, Aregeneratoric anemia
  • Ankara University Affiliated: Yes

Abstract

Aregeneratoric anemia (AA) occurs rarely after ABO-incompatible allogeneic peripheral blood stem cell transplantation (alloPBSCT), and its management is generally difficult. Here, we present a 31-year-old white man with myelodysplastic syndrome who developed AA after receiving stem cells from his human leukocyte antigen (HLA) identical, but ABO-incompatible sibling. Because his anti-A antibody titers were high, therapy with conventional doses of erythropoietin and prednisolone failed to treat the AA. Following 8 cycles of plasma exchange and higher doses of erythropoietin and prednisolone as well as danazol administration, anti-A titers decreased, and his anemia improved significantly. In conclusion, to treat and obtain a low titer of antibodies in a patient with AA following an ABO-incompatible alloPBSCT, higher doses of erythropoietin and corticosteroids associated with plasma exchange have to be used.